## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.13 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($200.12)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Does Johnson & Johnson’s 2025 Rally Still Offer Value After Strong DCF and PE Signals?**
- Source: Simply Wall Street | 20251222T090755 | Bullish | Relevance: 100%
- This article analyzes Johnson & Johnson's stock performance and valuation indicators, including Discounted Cash Flow (DCF) and Price to Earnings (PE) ratios. Despite a significant rally in 2025, the analysis suggests J&J appears undervalued by these metrics, with a DCF model indicating a 46.3% undervaluation. The article also introduces "Narratives," a tool for investors to connect their market views to forecasts and fair value estimates.

**2. Jury says Johnson & Johnson owes woman $65.5 million**
- Source: NBC News | 20251220T190832 | Bearish | Relevance: 100%
- A jury has ruled that Johnson & Johnson must pay a woman $65.5 million. The article headline indicates the core outcome of the legal case. No further details are provided within the short excerpt.

**3. 54,803 Shares in Johnson & Johnson $JNJ Bought by NatWest Group plc**
- Source: MarketBeat | 20251220T110848 | Bullish | Relevance: 100%
- NatWest Group plc acquired 54,803 shares of Johnson & Johnson (JNJ) in the third quarter, valued at approximately $10.16 million, making JNJ its 16th largest holding. Regulatory approvals for new J&J products, specifically a subcutaneous version of Rybrevant and the TRUFILL n‑BCA embolic system, are expected to enhance commercial prospects in oncology and MedTech. Despite potential near-term profit-taking risks after strong year-to-date gains, analysts maintain a "Moderate Buy" rating with a consensus price target of $210.25, supported by the company's strong fundamentals and dividend yield.

**4. Tim Schmid shares Johnson & Johnson MedTech’s growth playbook**
- Source: Medical Design & Outsourcing | 20251222T140323 | Somewhat-Bullish | Relevance: 100%
- Tim Schmid, EVP and global medtech chairman of Johnson & Johnson MedTech, outlines the company's new growth strategy, which includes spinning off DePuy Synthes to focus on cardiovascular, surgery, and vision. This strategic shift, bolstered by acquisitions like Abiomed and Shockwave Medical, aims to increase J&J MedTech's presence in high-growth markets and improve its financial performance. Schmid also discusses the future of J&J's surgical robotics (Ottava), vision business, and ongoing M&A and R&D investments.

**5. Rep. Thomas H. Kean, Jr. Sells Stryker Corporation (NYSE:SYK) Stock**
- Source: MarketBeat | 20251220T071017 | Neutral | Relevance: 72%
- Representative Thomas H. Kean, Jr. recently sold shares of Stryker Corporation (NYSE:SYK) valued between $15,001 and $50,000. This comes as Stryker increased its quarterly dividend and reported an EPS beat, though significant insider selling has occurred recently. Analyst ratings for Stryker currently average a "Moderate Buy" with a consensus price target of $431.84.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Goldman Sachs | $240 | $213 | +13% |
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |
| 2025-12-11 | Citigroup | $232 | $215 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Goldman Sachs | main | Buy |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +9%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.13 suggests fair value with growth premium. Forward P/E 18.0x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (7 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $499.5B |
| Beta | 0.35 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.13 |
| Forward P/E | 18.0 |
| Current P/E | 19.1 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.1% to -0.3% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.28% (CS: 44) | Neutral |
| RSI_14 | 56.7 | Neutral |
| MACD Histogram | -0.49 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.046x | Above |
| vs SMA200 | 1.201x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $207.26
- **Stop Loss:** $200.12 (3.4% risk)
- **Target:** $221.54 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 168
- **Position Value:** $34,819.68
- **Portfolio %:** 34.82%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*